The female pelvic implants market is projected to account for sales worth US$ 258.91 million by 2023. The market is projected to observe a CAGR of 2.8% in the forecast period, reaching US$ 341.26 million by 2033.
As per FMI, the top five players comprising Johnson & Johnson, Coloplast A/S, Becton, Dickinson and Company, Boston Scientific Corporation, and Cook Medical constitute around 75% of the overall market.
Market to Gain from Novel Tissue Engineering Launch for Female Pelvic Floor Reconstruction
Ongoing post-marketing surveillance of approved devices and the introduction of novel tissue engineering in female pelvic floor reconstruction creates huge opportunities in the female pelvic implants industry. The majority of manufacturers are selling their products in the global market despite strict regulations.
After the Food and Drug Administration’s (FDA) reclassification of vaginal mesh implants from Class II to Class III medical devices, the FDA has advised 33 manufacturers to conduct 3-year studies. It is to assess the impact of organ damage and other complications of mesh implants.
After assessing the risks, the manufacturers can reintroduce their devices and can get pre-market approval from the FDA. Further, this allows manufacturers to re-launch mesh implants, which are expected to enter the market. Similarly, the introduction of novel tissue engineering with growth factors, biomaterials, and drugs implanted into tissue damage or loss is set to boost repair time, stimulating the regeneration of damaged tissue.
Studies initiating tissue engineering for pelvic organ prolapse have reported the use of novel designed knit material fabricated from FDA-approved non-degradable polyamide dip-coated in gelatin for MSC seeding and delivery.
Polypropylene mesh commonly used in clinical practice has good mechanical properties, but there are long-term complications. This validates the need for tissue engineering technology in the treatment of pelvic organ prolapse and promotes an innovative approach to pelvic implantation.
What are the Factors Restraining Demand for Female Pelvic Implants?
As per the USFDA, the transvaginal placement of surgical mesh can be risky in women with POP mesh complications. Some of the common complications reported include mesh erosion, infections, vaginal scarring, discomfort and pain during sex, and even a resurgence of urinary incontinence.
Through January 31, 2019, over 139,000 adverse events have been reported for mesh products of which over 69,000 events were reported for POP mesh products, as per FDA, 2020. This restricts the patients from taking surgeries to implant vaginal mesh, thereby deterring market growth.
Growing awareness of surgical complications is curbing patients from opting for vaginal mesh implants in the high-growth markets of Europe and the United States.
| Attributes | Details |
|---|---|
| Female Pelvic Implants Market Size (2023) | US$ 258.91 million |
| Female Pelvic Implants Market Size (2033) | US$ 341.26 million |
| Female Pelvic Implants Market CAGR (2023 to 2033) | 2.8% |
| Female Pelvic Implants Market Size (2022) | US$ 251.86 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights (FMI), the demand for female pelvic implants has grown at a 2.5% CAGR between 2018 and 2022.
According to the Division of Female Pelvic Medicine and Reconstructive Surgery at Northwestern University Chicago, women with normal life expectancy have an average 30-50% chance of developing pelvic organ prolapse. Around 19% of these women need to undergo at least one surgical intervention for POP or SUI and 30% of them undergo reoperation for recurrence. Despite such high prevalence, there is no definite cure or restoration of anatomical defects for pelvic organ prolapse or stress urinary incontinence.
In the last two decades, many efforts have been made to improve the outcomes of surgery. However, the majority of such efforts have resulted in the use of vaginal mesh and grafts. So far, surgical options with mesh implants and slings are proving to be the best option for such disorders which imply a heavy social and economic burden.
Other surgical options such as allografts and xenografts are costly and carry the potential of transmission of infectious disease and synthetic meshes. Thus, the market for female pelvic implants is expected to see continuous growth in the use of mesh and sling implants until definite alternatives are available for these products.
Future Market Insights expects the global female pelvic implants industry to rise at 2.8% CAGR between 2023 and 2033.
The United States holds over 83% share of the female pelvic implants market in North America. As per the records of the Association for Pelvic Organ Prolapse Support, nearly 34 million women suffer from pelvic organ prolapse (POP) across the globe currently.
In the United States, the overall number of patients with POP is 3.3 million. According to the National Association for Incontinence, 25 million people in the United States suffer from some form of urinary incontinence, out of which 75% are women. Stress urinary incontinence (SUI) is the most prevalent form.
In the United States, about 15 million people are suffering from SUI. Thus, the rising prevalence of pelvic organ prolapse and stress urinary incontinence is driving the United States female pelvic implant market.
The United Kingdom market accounts for over 13% of Europe market through the assessment period ending in 2033. The governments of various countries in Europe like the United Kingdom are forming committees that can address the issues of women suffering from peri-operative complications of surgeries for pelvic implants. These programs are expected to raise awareness among patients, hospitals, and GPs and can increase the penetration of female pelvic implants over the forecast period. For instance,
India’s market accounts for more than 30% of the sales registered in South Asia in 2021. Most developing countries have patients that are not aware of conditions such as pelvic organ prolapse and stress urinary incontinence.
Perception of pain associated with surgery evokes considerable anxiety in patients resulting in a reluctance to consider surgical options to cure SUI or POP. Many women delay or do not seek treatment for these diseases in India due to a lack of awareness. It is forecasted to be the big challenge for the growth of female pelvic implants in India market.
| Country | Australia |
|---|---|
| Forecast CAGR % (2023 to 2033) | 2.8% |
The market for female pelvic Implants in Australia is exhibiting a 2.8% CAGR and is projected to account for more than 86% of Oceania market throughout the projection period. Growing government initiatives to create awareness are anticipated to boost growth in the region. For instance,
Principal Consultant
| Segment | Vaginal Sling/Tapes |
|---|---|
| Forecast CAGR (2023 to 2033) | 2.5% |
Vaginal sling/tapes have a high growth potential. The segment is likely to expand with a relatively high CAGR of 2.5% in the forthcoming years. Vaginal sling/tape implants are generally made from a narrow ‘tape’ of polypropylene mesh which is placed under the urethra like a sling or hammock to keep the urethra in the correct position.
Vaginal slings have been on the market for about 20 years and can be implanted in half-hour. The minimally invasive surgical procedure under local anesthesia is preferred for outpatient applications. Owing to these advantages, demand for vaginal sling/tapes is increasing during the forecast period.
The stress urinary incontinence (SUI) segment is expected to contribute maximum revenue share in the global female pelvic implants market. In terms of revenue, the stress urinary incontinence (SUI) segment accounted for over 58% share in 2022.
The demand for female pelvic implants is likely to witness solid growth on account of the prevalence of stress urinary incontinence and rising awareness among women regarding treatment options on a global scale.
| Segment | Hospitals |
|---|---|
| Forecast CAGR (2023 to 2033) | 2.2% |
Hospitals are currently the leading end users of female pelvic implants with a 2.2% CAGR through the forecast period. Similarly, hospitals can impact high investment abilities and capital, with the surge in the number of emergency admissions, which is projected to enhance growth prospects for the long term.
Manufacturers are primarily focusing on developing new products to bolster the acceptance of female pelvic implants, thus anticipating the surge in sales figures. Further, the companies are focusing on outsourcing the production of female pelvic implants to reduce manufacturing costs, thereby challenging the market with reduced costs.
Key players are entering into collaborations, partnerships, acquisitions, and mergers to strengthen their product lines and global market.
Key Players Working in the Market:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ Million for Value in Million |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania Middle East & Africa |
| Key Countries Covered | The United States, Canada, the United Kingdom, Germany, Italy, France, Spain, Benelux, Russia, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa and North Africa |
| Key Segments Covered | Product Type, Indication, End User, and Region |
| Key Companies Profiled | Johnson & Johnson Services, Inc.; Coloplast A/S; Dipromed Srl; Boston Scientific Corporation; pfm medical ag; Betatech Medical; Promedon Group; Caldera Medical; Cook Medical |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The CAGR for the market is 2.8% until 2033.
From 2018 to 2022, the market expanded at an 2.5% CAGR.
The market in 2023 totals US$ 258.91 million.
Promedon Group, Caldera Medical, Cook Medical are some key players.
The market will reach US$ 341.26 million by 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
5.3.1. Vaginal Mesh Implants
5.3.2. Vaginal Sling
5.3.3. Vaginal Graft Implants
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
6.3.1. Pelvic Organ Prolapse
6.3.2. Stress Urinary Incontinence
6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals
7.3.2. Ambulatory Surgical Centres
7.3.3. Speciality Clinics
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East & Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Product Type
9.2.3. By Indication
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Indication
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Argentina
10.2.1.4. Rest of Latin America
10.2.2. By Product Type
10.2.3. By Indication
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Indication
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. UK
11.2.1.2. Germany
11.2.1.3. France
11.2.1.4. Italy
11.2.1.5. Spain
11.2.1.6. Rest of Western Europe
11.2.2. By Product Type
11.2.3. By Indication
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Indication
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Russia
12.2.1.2. Poland
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Product Type
12.2.3. By Indication
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Indication
12.3.4. By End User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Product Type
13.2.3. By Indication
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Indication
13.3.4. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Product Type
14.2.3. By Indication
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Indication
14.3.4. By End User
14.4. Key Takeaways
15. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Iran
15.2.1.2. Turkey
15.2.1.3. Rest of MEA
15.2.2. By Product Type
15.2.3. By Indication
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product Type
15.3.3. By Indication
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Product Type
16.1.2.2. By Indication
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Product Type
16.2.2.2. By Indication
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Product Type
16.3.2.2. By Indication
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Product Type
16.4.2.2. By Indication
16.4.2.3. By End User
16.5. Argentina
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Product Type
16.5.2.2. By Indication
16.5.2.3. By End User
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Product Type
16.6.2.2. By Indication
16.6.2.3. By End User
16.7. Germany
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Product Type
16.7.2.2. By Indication
16.7.2.3. By End User
16.8. France
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Product Type
16.8.2.2. By Indication
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Product Type
16.9.2.2. By Indication
16.9.2.3. By End User
16.10. Spain
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Product Type
16.10.2.2. By Indication
16.10.2.3. By End User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Product Type
16.11.2.2. By Indication
16.11.2.3. By End User
16.12. Poland
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Product Type
16.12.2.2. By Indication
16.12.2.3. By End User
16.13. Czech Republic
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Product Type
16.13.2.2. By Indication
16.13.2.3. By End User
16.14. Romania
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Product Type
16.14.2.2. By Indication
16.14.2.3. By End User
16.15. India
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Product Type
16.15.2.2. By Indication
16.15.2.3. By End User
16.16. Bangladesh
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Product Type
16.16.2.2. By Indication
16.16.2.3. By End User
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Product Type
16.17.2.2. By Indication
16.17.2.3. By End User
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Product Type
16.18.2.2. By Indication
16.18.2.3. By End User
16.19. China
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Product Type
16.19.2.2. By Indication
16.19.2.3. By End User
16.20. Japan
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Product Type
16.20.2.2. By Indication
16.20.2.3. By End User
16.21. South Korea
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Product Type
16.21.2.2. By Indication
16.21.2.3. By End User
16.22. Iran
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Product Type
16.22.2.2. By Indication
16.22.2.3. By End User
16.23. Turkey
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Product Type
16.23.2.2. By Indication
16.23.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Product Type
17.3.3. By Indication
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Johnson & Johnson Services, Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Coloplast A/S
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Dipromed Srl
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Boston Scientific Corporation
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. pfm medical ag
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Betatech Medical
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Promedon Group
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Caldera Medical
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Cook Medical
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Healthcare
March 2024
REP-GB-2533
195 pages
Explore Healthcare Insights
View Reports
Female Pelvic Implants Market
